Neuralink competitor Paradromics gets one step closer to FDA approval for its brain implant

05/19 20:30

Paradromics, a neurotech startup based in Austin, Texas, has received the Breakthrough Device designation from the Food and Drug Administration (FDA) for its brain implant system called Connexus Direct Data Interface. The device is designed to help patients with severe paralysis regain their ability to communicate by deciphering their neural signals. The breakthrough designation will help Paradromics bring its device to market faster and create a "fast track" for communication between the FDA and Paradromics. The company hopes to launch its first clinical trial with human patients in the first half of 2024.

BullishBearishGostoPartilhar

Isenção de responsabilidade：O conteúdo acima não representa as posições da HTX.，A HTX não faz quaisquer recomendações de negociação.。